Vagus nerve stimulation for mild preeclampsia
Official title: Vagal Autonomic Stimulation Physiotherapy (With Trigger Point Release) as an Adjunct to Personalized Antihypertensive Management of Gestational Hypertension Syndrome and Preeclampsia
Run by Fundación Internacional René Mey · NCT06953115 · Data updated 2026-11-12
This trial will try vagus‑nerve stimulation physiotherapy (trigger point release and positional release) to help control blood pressure and inflammation in pregnant women with mild preeclampsia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 210 (estimated) |
| Sponsor | Fundación Internacional René Mey Academic / other |
| Locations | 4 sites (Guadalajara, Jalisco and 3 other locations) |
| Status | Recruiting |
| Started | October 15, 2026 |
| Main results expected | May 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT06953115 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant women over 18 with newly diagnosed mild preeclampsia who have not received prior treatment and can attend outpatient visits at the listed IMSS sites in Guadalajara.
✕Probably not a fit
Patients with severe preeclampsia, chronic hypertension, organ dysfunction, immunological disease, or gestational trophoblastic disease are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study applies noninvasive vagal stimulation using physiotherapy techniques (trigger point release and positional release) to pregnant women with newly diagnosed mild preeclampsia. Participants are outpatient women over 18 seen at IMSS hospitals in Guadalajara and must not have chronic hypertension or other major comorbidities. The intervention aims to activate the cholinergic anti‑inflammatory pathway via the vagus nerve to improve blood pressure control and placental blood flow. Safety, blood pressure, inflammatory markers, and pregnancy outcomes will be monitored during follow‑up.
Why it matters
Potential benefit: If successful, the approach could lower maternal blood pressure and inflammation, reducing the risk of severe complications and improving outcomes for mother and baby.
How similar studies have gone: Preclinical models have shown promising blood pressure and inflammation effects from vagal stimulation, and some small clinical uses of vagal techniques exist, but rigorous clinical evidence specifically for preeclampsia is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Outpatient female patients over 18 years old, attending their first appointment and seen in the obstetrics outpatient clinic at the Regional General Hospitals of IMSS Jalisco, with a pregnancy complicated by confirmed mild preeclampsia. * No prior treatment. * Willing to participate by signing an informed consent form. Exclusion Criteria: * Patients with chronic hypertension. * Concomitant organ dysfunction. * Immunological diseases. * Patients with severe preeclampsia or chronic conditions concomitant with pregnancy. * Patients with gestational trophoblastic disease requiring uterine evacuation or choriocarcinoma associated with hypertension.
Where it's running
-
Hospital General de Zona 110, IMSS
Guadalajara, Jalisco, Mexico Recruiting -
Unidad de Investigación Biomédica 02, UMAE HE CMNO IMSS
Guadalajara, Jalisco, Mexico Not yet recruiting -
Hospital General de Zona 46, IMSS
Guadalajara, Jalisco, Mexico Not yet recruiting -
Hospital General de Zona 180, IMSS
Tlajomulco de Zúñiga, Jalisco, Mexico Not yet recruiting
Study contacts
- Principal investigator: René Jaques Mey, Dr. h.c. — Fundación Internacional René Mey
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
-
Aspirin with or without low‑molecular‑weight heparin to prevent preeclampsia in high‑risk pregnancy
This trial tests whether adding low‑molecular‑weight heparin (tinzaparin) to low‑dose aspirin reduces the chance of preeclampsia in pregnant people identified as high risk in the first trimester.
-
Blood markers (sFlt-1/PlGF, sEng, OPG) for diagnosing and monitoring preeclampsia
This study will test whether three blood markers—the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)—can help diagnose and track preeclampsia in pregnant women between 20 and 36 weeks of gestation.
-
Postpartum high blood pressure: trying enalapril after delivery
This study tests whether giving enalapril after delivery can help postpartum women with hypertensive disorders of pregnancy manage blood pressure.
-
Spironolactone to improve blood pressure after pregnancy-related hypertension
This trial will try taking spironolactone for three months after delivery to see if it lowers blood pressure and prevents heart changes in women who had preeclampsia or gestational hypertension and were overweight before pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.